VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

What Was Tested

In this phase 3 trial, researchers set out to test VK2735.

It had four arms (groups): Placebo Assignment (placebo comparator), one (experimental), one (experimental) and one (experimental).

VK2735 Placebo Comparator Once Weekly.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 1100 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18 years of age at the time of signing the informed consent. Body mass index (BMI) ≥27 kg/m2.

The full record lists 3 inclusion and 11 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening); have type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except type 2 diabetes mellitus (t2dm); have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

Because people in this VK2735 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The VK2735 group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received VK2735.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2025-06-23 with completion listed for 2027-07-01.

It ran at 127 sites in United States (125) and Puerto Rico (2).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent change in body weight from baseline to Week 78 in body weight (time frame: 78 Weeks).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of VK2735 in 1100 people.

With 1100 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the VK2735 compound page, all human trials.